Ankylosing Spondylitis Market Present Scenario, Industry Analysis by Revenue, Size, Share and Forecast | Cipla Inc., Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd., UCB S.A.

Market Overview:

Ankylosing spondylitis is a type of spinal arthritis that causes inflammation of the joints of the spine and pelvis. Common symptoms include lower back pain and stiffness that usually improves with exercise. Commonly used medications for ankylosing spondylitis treatment include non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen to relieve pain and stiffness and disease-modifying anti-rheumatic drugs (DMARDs) like sulfasalazine to slow disease progression.

Market Dynamics:

Growing incidence of ankylosing spondylitis worldwide is estimated to drive the market growth over the forecast period. According to the Spondylitis Association of America, Ankylosing spondylitis is estimated to affect around 0.1-1.4% of the global population. In addition, sedentary lifestyle making population susceptible to spine problems will also contribute to the rising cases of ankylosing spondylitis. Furthermore, new product launches by key companies is also expected to boost the ankylosing spondylitis market growth during 2023-2030. For instance, in 2020, UCB launched Cimzia injection for treatment of ankylosing spondylitis. Moreover, increasing R&D investment by pharmaceutical companies for developing novel biologics with improved efficacy is expected to offer lucrative growth opportunities for market players in the forecast period.

Get an Exclusive Sample Copy of the Report at: - https://www.coherentmarketinsights.com/insight/request-sample/4833

Driver: growing awareness and diagnosis of ankylosing spondylitis is propelling the market growth

Ankylosing spondylitis is gaining more attention from public and healthcare professionals due to the rising cases worldwide. Various awareness programs organized by patient advocacy groups and government bodies are educating people about the symptoms and management of this chronic disease. This is resulting in early diagnosis and treatment-seeking behavior. Furthermore, advancement in diagnostic technologies such as MRI and CT scanning have improved the detection rate of ankylosing spondylitis. The medical community is also well-informed now about this disease and can recognize it early in patients. As a consequence of enhanced awareness and diagnosis, the demand for drugs and other therapy options to manage ankylosing spondylitis is accelerating in the market.

Driver: entry of novel pipeline drugs offering more efficacy and safety is fueling competition

The active research and development activities of pharmaceutical companies have brought several new molecules in the ankylosing spondylitis treatment landscape. These pipeline entities offer more targeted mechanisms of action, improved safety-efficacy profiles, and novel drug delivery systems. For instance, substances blocking IL-23 and IL-17 pathways are demonstrating promising results in clinical trials. Some pipeline candidates even have the potential to achieve remission in patients by modifying disease progression. The approvals of such innovative drugs in the market will provide clinicians with more options to individualize therapies bases on patients' response and comorbidities. This vibrant drug pipeline and availability of better treatment alternatives are giving a competitive edge to the ankylosing spondylitis market.

Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, a detailed analysis of the competitive landscape, and product services of key players. Analysis of Ankylosing Spondylitis companies, key tactics followed by Leading Key Players:

◘ Amgen Inc.
◘ AbbVie Inc.
◘ Pfizer Inc.
◘ Novartis AG
◘ Bristol-Myers Squibb Company
◘ CELGENE CORPORATION
◘ Eli Lilly and Company
◘ Cipla Inc.
◘ Emcure Pharmaceuticals
◘ Torrent Pharmaceuticals Ltd.
◘ UCB S.A.
◘ Suzhou Zelgen Biopharmaceuticals Co., Ltd.,
◘ HENGRUI USA
◘ Johnson & Johnson Services Inc.

Restrain: high cost of biologic drugs remains a challenge in market growth

Though biologic drugs have revolutionized the treatment of ankylosing spondylitis, their extraordinary pricing puts them out of reach for many patients. These biologics require lifelong administration and cost anywhere between $20,000 to $50,000 per patient annually in the US. The financial burden is severe especially in developing nations with limited public health coverage for such expensive specialty medications. Even in developed countries, not every patient is eligible for insurance reimbursements, leaving them dependent on expensive out-of-pocket payments or charities. The prohibitive cost of biologics restricts widespread access and compliance to treatment, which acts as a restraint for the overall market growth.

Opportunity: expanding applications in comorbid diseases can offer lucrative opportunities

Ankylosing spondylitis is often associated with other inflammatory diseases such as psoriasis, ulcerative colitis, and Crohn's disease owing to shared inflammatory mechanisms. Drugs approved for ankylosing spondylitis are now finding applications in managing certain extra-articular manifestations as well relevant comorbidities. For instance, tumor necrosis factor (TNF) inhibitors work for both axial spondyloarthritis and psoriatic arthritis. This offers an opportunity to expand drug indications and leverage the large patient population of associated diseases. Companies investing in exploring comorbidity links through collaborative research can access untapped markets. Such diverse application profiling may further augment the returns on drug development for ankylosing spondylitis.

Trend: adoption of combination therapies is emerging as strategic trend

Based on better understanding of disease pathogenesis, researchers recognize that ankylosing spondylitis involves multiple inflammatory pathways rather than a single target. Therefore, a strategic trend gaining prominence is the use of combination drug regimens - typically a biologic along with a conventional DMARD (disease-modifying anti-rheumatic drug). Such dual therapy synergizes the effects and optimizes outcomes. Combination modules allow lowering the biologic dose for improved safety. They also help prevent or delay immunogenicity and resistance known to develop with long-term biologic monotherapy. Many clinical trials are currently evaluating different combination regimens for ankylosing spondylitis. This emerging preference for strategic drug combinations among physicians is a notable trend that can strengthen the competitiveness of market players.

Buy This Premium Report and Get Upto 25 % OFF: https://www.coherentmarketinsights.com/insight/buy-now/4833

The Study Objectives are:

A comprehensive insight into key players operating in the Ankylosing Spondylitis Market and their corresponding data.
It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
Regional analysis, which includes insight into the dominant market and corresponding market share.
It also includes various socio-economic factors affecting the evolution of the market in the region.
The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.
Table of Contents:

Market scenario 2023

Chapter 1: Introduction, Market Driving Force Product Objective of Study and Research Scope the Ankylosing Spondylitis market
Chapter 2: Exclusive Summary - the basic information of the Ankylosing Spondylitis Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends, and Challenges & Opportunities of the Ankylosing Spondylitis
Chapter 4: Presenting the Ankylosing Spondylitis Market Factor Analysis, Supply/Value Chain, PESTEL analysis, Market Entry, and Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User, and Region/Country 2023 - 2030
Chapter 6: Evaluating the leading manufacturers of the Ankylosing Spondylitis market which consists of its Competitive Landscape, Peer Group Analysis, Market positioning & Company Profile
Chapter 7: To evaluate the market by segments, by countries, and by Manufacturers/Companies with revenue share and sales by key countries in these various regions (2023-2030)
Chapters 8 & 9: Displaying the Appendix, Methodology, and Data Source

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/4833

Key Questions Answered:

What is the market size and CAGR of the Ankylosing Spondylitis Market during the forecast period?
How is the growing demand impacting the growth of Ankylosing Spondylitis Market shares?
What is the growing demand of the Market during the forecast period?
Who are the leading vendors in the market and what are their market shares?
What is the impact of the COVID-19 pandemic on the APAC Ankylosing Spondylitis Market?

Contact Us

Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States
Phone: US +12067016702 / UK +4402081334027
JAPAN:+81-50-5539-1737
INDIA:+91-848-285-0837
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.